Saniona spins out cancer project in new firm

Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.

The photo does not depict the Scandion Oncology drug.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Latest Top picks in English

Related articles